WallStSmart

Microbot Medical Inc (MBOT)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 27752282% more annual revenue ($29.14B vs $105,000). MDLN leads profitability with a 3.3% profit margin vs 0.0%. MDLN earns a higher WallStSmart Score of 55/100 (C-).

MBOT

Avoid

34

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 6.0Quality: 8.5
Piotroski: 3/9Altman Z: 10.40

MDLN

Buy

55

out of 100

Grade: C-

Growth: 7.3Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.79

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MBOT4 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
10.4010/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.708/10

Growing faster than its price suggests

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

MBOT4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$132.99M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

MDLN4 concerns · Avg: 3.5/10
P/E RatioValuation
31.4x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.794/10

Distress zone — elevated risk

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Debt/EquityHealth
1.123/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : MBOT

The strongest argument for MBOT centers on Debt/Equity, Altman Z-Score, PEG Ratio. PEG of 0.70 suggests the stock is reasonably priced for its growth.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : MBOT

The primary concerns for MBOT are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

MDLN is growing revenue faster at 10.7% — sustainability is the question.

MDLN generates stronger free cash flow (316M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (55/100 vs 34/100) and 10.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Microbot Medical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Microbot Medical Inc., a preclinical medical device company, researches, designs and develops micro-robotic-assisted medical technologies targeting the minimally invasive surgery space. The company is headquartered in Hingham, Massachusetts.

Visit Website →

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?